Chronic Kidney Disease Drugs Market – Insights
Chronic kidney disease (CKD) involves gradual loss of functioning of kidneys. The normal function of kidneys are to filter out and excrete wastes, and excess fluids from the blood are excreted through urine. However, when an individual is suffering from chronic kidney disease, kidneys cannot perform their natural function and wastes, fluids, and electrolytes build up in the body in excess amounts. Signs and symptoms of chronic kidney disease are not apparent until kidney function becomes significantly impaired. The supportive treatment of chronic kidney disease includes delaying the disease progression and kidney damage. Diseases and conditions such as type 1 or type 2 diabetes, high blood pressure, polycystic kidney disease, and recurrent kidney infection leads to chronic kidney disease. Factors that increase risk of chronic kidney disease include diabetes, high blood pressure, smoking, obesity, and others. Management of the disease involves managing the co-morbidities such as blood pressure, diabetes medications, medications to lower cholesterol levels, and anemia treatment. Kidney dialysis and kidney transplant may become a necessity, as the condition becomes worse. There is no direct medication available for the treatment of chronic kidney disease. Chronic kidney diseases may trigger other healthcare issues such as cardiovascular diseases.
High prevalence of diseases leading to chronic kidney diseases are expected to foster growth of the chronic kidney disease drugs market
Diseases such as diabetes and high blood pressure increase the risk of chronic kidney diseases. According to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. are estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease, which indicates the underlying market potential in chronic kidney disease drugs market. Moreover, according to CDC, high blood pressure and diabetes are leading causes of chronic kidney disease. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. According to the American Diabetes Association (ADA), in 2015, 30.3 million people in the U.S. were suffering from diabetes. According to CDC, in 2014, around 118,000 people in the U.S. started the treatment for end stage renal disease and as more people become aware of this condition, the number of people for treatment will increase. These factors are expected to boost the market growth over the forecast period.
The global chronic kidney disease drugs market was valued at US$ 12,468.2 million in 2017 and is expected to witness a robust CAGR of 3.1% over the forecast period (2018 – 2026).
Figure 1. Global Chronic Kidney Disease Drugs Market Share, by Region, 2018
Initiatives taken by government organizations and manufacturers to increase awareness of chronic kidney disease is expected to boost the market growth over the forecast period
Individual government organizations and manufacturers are working towards increasing the awareness of chronic kidney diseases. For instance, American Kidney Fund (AKF) launched comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). In March 2018, Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Moreover, CVS Health Corporation launched kidney disease initiative in April 2018. In March 2018, Fresenius Medical North America (FMCNA) made a contribution of US$ 40,000 to Kidney School, world’s largest education program for people with chronic kidney disease.
However, delay in the diagnosis of chronic kidney disease is expected to hinder growth of the chronic kidney disease drugs market over the forecast period.
Some major players operating in the chronic kidney disease drugs market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
Chronic kidney disease can be controlled and prevented from worsening with the help of kidney friendly diet plans and efficiently managing other diseases, which may lead to chronic kidney diseases. For instance, facts such as maintaining a healthy blood pressure, having a low-salt and low-fat diet, control blood sugar, regular exercise, and avoiding smoking and drinking may prevent chronic kidney disease from worsening. Another form of kidney disease is acute kidney disease, which occurs directly due to disorders affecting kidney such as inadequate blood supply and improper urine flow from kidneys. Apart from medication management, other treatment options for end stage renal diseases include dialysis and kidney transplant.
The global chronic kidney disease drugs market is driven by factors such as increasing prevalence of chronic kidney disease and high presence of generic drug manufacturers in the market. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. Individual government organizations and manufactures are indulged in research and development as well as increasing awareness about chronic kidney diseases, which is fostering growth of the chronic kidney disease drugs market. In March 2018, the Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Continuous requirement of medication coupled with easy availability of drugs is expected to boost growth of chronic kidney disease drugs market over the forecast period. However, absence of novel treatment option and delay in diagnosis of the disease due to vague symptoms are expected to hinder growth of the chronic kidney disease drugs market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 29 market data tables and 47 figures on "Chronic Kidney Disease Drugs Market - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.